Study of KBP-7072 in Healthy Male and Female Subjects
Study Details
Study Description
Brief Summary
This is a double-blind, randomized, placebo-controlled, single and multiple IV dose study conducted in two parts. Part A (SAD) will comprise an ascending single dose, sequential group design. Each subject will participate in 1 treatment period only. Subjects will reside at the study site from check-in on Day -1 (the day before dosing) to discharge on Day 8. In Part A, serial blood and urine collections will be obtained on Day 1 pre-dose through 168 hours post start of infusion for analysis of plasma and urine concentrations of KBP-7072 and KBP-6079. Safety will be monitored through recording of adverse events, clinical laboratory evaluations, vital sign measurements, 12-lead ECG and physical examination findings. Part B (MAD) will comprise an ascending multiple dose, sequential group study. Each subject will participate on one treatment period only and reside at the study site from check-in on Day -1 until discharge on Day 17. In Part B, serial blood and urine collections will be obtained on Day 1 pre-dose through 24 hours post start of infusion and on Day 10 pre-dose through 168 hours post start of infusion for analysis of plasma and urine concentrations of KBP-7072 and KBP-6079. Trough blood sample collections for analysis of plasma concentrations of KBP-7072 and KBP-6079 will be obtained pre-dose on Days 3, 4, 5, 6, 7, 8 and 9. Safety will be monitored through recording of adverse events, clinical laboratory evaluations, vital sign measurements, 12-lead ECG and physical examination findings.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 1 |
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: KBP-7072 Proposed dose levels for Part A: 25, 50, 100, 150 and 200mg KBP-7072. Proposed dose levels for Part B: 50 and 100mg. Administration route is intravenous infusion. |
Drug: KBP-7072
KBP-7072
|
| Placebo Comparator: Placebo Placebo for intravenous infusion. |
Drug: Placebo
Placebo
|
Outcome Measures
Primary Outcome Measures
- Number of participants with adverse events, with abnormal laboratory test results, abnormal ECGs, abnormal vital signs, and abnormal physical examinations [Time Frame: SAD 1- 7 days and MAD 1-17 days]
Safety Assessment evaluated through adverse events, laboratory evaluations, vital signs, ECGs, and physical examination.
Secondary Outcome Measures
- Pharmacokinetics Parameters :AUC from time 0 extrapolated to infinity (AUC0-∞) [SAD Day 1 predose (within the 30 minutes prior to dosing) and at 5, 15,30,45 minutes and at 1,1.5,2,4,6,10,12,24 (day 2), 48 (Day 3), 72 (Day 4), 96 (Day 5), 120 (Day 6), 144 (Day 7) and 168 (Day 8) hour(s) post start of infusion]
AUC from time 0 extrapolated to infinity (AUC0-∞)
- Pharmacokinetics Parameters: Area under the plasma concentration-time curve (AUC) from time zero to time of last quantifiable concentration (AUC0-tlast), [SAD Day 1 predose (within the 30 minutes prior to dosing) and at 5, 15,30,45 minutes and at 1,1.5,2,4,6,10,12,24 (day 2), 48 (Day 3), 72 (Day 4), 96 (Day 5), 120 (Day 6), 144 (Day 7) and 168 (Day 8) hour(s) post start of infusion]
Area under the plasma concentration-time curve (AUC) from time zero to time of last quantifiable concentration (AUC0-tlast) - Plasma
- Pharmacokinetics Parameters: AUC over a dosing interval (AUC0-τ), from time zero to time of last quantifiable concentration (AUC0-tlast)from time zero to time of last quantifiable concentration (AUC0-tlast) [MAD samples will be collected on Day 1 pre-dose and at 5, 15, 30, 45 minutes, and at 1, 1.5, 2, 4, 6, 10, 12, 24 (Day 2) hours, pre-dose samples at 48 (Day 3), 72 (Day 4), 96 (Da]
AUC over a dosing interval (AUC0-τ) - Plasma
- Pharmacokinetics Parameters: Maximum observed plasma concentration (Cmax) [SAD Day 1 predose (within the 30 minutes prior to dosing) and at 5, 15,30,45 minutes and at 1,1.5,2,4,6,10,12,24 (day 2), 48 (Day 3), 72 (Day 4), 96 (Day 5), 120 (Day 6), 144 (Day 7) and 168 (Day 8) hour(s) post start of infusion]
Maximum observed plasma concentration (Cmax) - Plasma
- Pharmacokinetics Parameters: time of the maximum observed plasma concentration (Tmax) [SAD Day 1 predose (within the 30 minutes prior to dosing) and at 5, 15,30,45 minutes and at 1,1.5,2,4,6,10,12,24 (day 2), 48 (Day 3), 72 (Day 4), 96 (Day 5), 120 (Day 6), 144 (Day 7) and 168 (Day 8) hour(s) post start of infusion]
Time of the maximum observed plasma concentration (Tmax) - Plasma
- Pharmacokinetics Parameters: apparent terminal elimination half-life (t1/2) [SAD Day 1 predose (within the 30 minutes prior to dosing) and at 5, 15,30,45 minutes and at 1,1.5,2,4,6,10,12,24 (day 2), 48 (Day 3), 72 (Day 4), 96 (Day 5), 120 (Day 6), 144 (Day 7) and 168(Day 8) hour(s) post start of infusion]
Apparent terminal elimination half-life (t1/2) - Plasma
- Pharmacokinetics Parameters: observed accumulation ratio based on AUC0-τ (ARAUC0-τ) [MAD samples will be collected on Day 1 pre-dose and at 5, 15, 30, 45 minutes, and at 1, 1.5, 2, 4, 6, 10, 12, 24 (Day 2) hours, pre-dose samples at 48 (Day 3), 72 (Day 4), 96 (Da]
Observed accumulation ratio based on AUC0-τ (ARAUC0-τ) - Plasma
- Pharmacokinetics Parameters: amount of drug excreted in urine (Ae) [SAD Day 1 predose (within the 30 minutes prior to dosing) and at 5, 15,30,45 minutes and at 1,1.5,2,4,6,10,12,24 (day 2), 48 (Day 3), 72 (Day 4), 96 (Day 5), 120 (Day 6), 144 (Day 7) and 168(Day 8) hour(s) post start of infusion]
Amount of drug excreted in urine (Ae) - Urine
Eligibility Criteria
Criteria
Inclusion Criteria:
-
BMI between 18 and 30 kg/m2 at the time of screening
-
In good health, determined b no clinically significant findings from medical history, physical examination, 12-lead ECG, vital sign measurements and clinical laboratory evaluations
-
Females of nonchildbearing potential defined as permanently sterile or postmenopausal.
Males will agree to use contraception.
Exclusion Criteria:
-
Significant history or clinical manifestation of any metabolic, allergic, dermatological, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, neurological, respiratory, endocrine or psychiatric disorder as determined by the investigator.
-
Abnormal results of ophthalmologic examination within 3 months prior to dosing self-reported by subject.
-
Supine systolic blood pressure > 140 mmHg and/or diastolic blood pressure > 90 mmHg.
-
Triglycerides > 200 mg/dL
-
Total cholesterol > 240 mg/dL or LDL >190 mg/dL or HDL < 40 mg/dL
-
Positive urine drug screen at screening or check-in or positive blood alcohol test result at check-in.
-
Positive hepatitis panel and/or positive HIV test
-
Administration of a Covid-19 vaccine in the past 28 days prior to dosing
-
Interpretation of liver ultrasound with presence of fatty liver disease
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Parexel International - Early Phase Clinical Unit | Baltimore | Maryland | United States | 21225 |
Sponsors and Collaborators
- KBP Biosciences
- Parexel
Investigators
- Principal Investigator: Ronald Goldwater, Parexel
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- KBP7072-1-004